肥胖 - 管道分析：2023 年

肥胖是一个公共卫生问题，其患病率在全球范围内不断上升。 它现在如此流行，以至于被美国医学协会 (2013) 和欧盟委员会 (2021) 列为慢性病。 肥胖对生活质量有重大影响，导致医疗保健成本增加，肥胖者会产生多种健康风险，包括心血管疾病、2 型糖尿病、某些癌症和肌肉骨骼疾病。据说会增加患以下疾病的风险

本报告探讨了肥胖症，并按阶段概述了肥胖症、管道趋势、竞争格局和管道药物。

内容

概览

肥胖目标

• 介绍
• 流行病学和病因学
• 肥胖的病理生理学
• 肥胖的发病机制
• 胰高血糖素样□-1 (GLP-1) 在肥胖症中的作用
• 2022 年肥胖治疗指南
• 为患者选择最合适的减肥药提供基于证据的建议
• 治疗可能导致肥胖的 T2D（2 型糖尿病）的非处方药

肥胖管道分析，按阶段

• 肥胖 - III 期和 II 期管道分析摘要
• 按开发阶段划分的管道产品
• 肥胖症竞争格局，按阶段、按路线
• 临床管线（3 期-1 期）产品，按公司分类
• 肥胖症单一疗法和联合疗法的临床试验
• 按作用机制分类的在研产品
• 早期和临床阶段的新机制
• 肥胖临床和监管时间表
• 后期概况比较概览

肥胖许可、收购和合作

肥胖管道景观

• 肥胖症临床管线状态

第三阶段

• Kagrisema（诺和诺德 A/S）
• DOR/3TC/TDF（默克公司）
• Tilzepatide（礼来公司）
• IBI362（信达生物製品（苏州）有限公司）

肥胖管道景观

第二阶段

• DCCR（Soleno Therapeutics, Inc.）
• MBL949（诺华）
• BI 456906（Zealand Pharma/Boehringer Ingelheim）
• LY3502970（礼来公司）
• XW-003（Sciwind Biosciences）
• ARD-101（土豚疗法）
• 达努列酮（辉瑞）
• PF-07081532 (Sosei Heptares)
• Pembidutide（Altimmune, Inc.）
• Retatortide（礼来公司）
• TG103（Genexine/天境生物/石药集团）
• APHD-012（Aphaia 製药公司）
• Bimagrumab（Versanis Bio, Inc./Novartis）
• HSG4112 (Glaceum)
• SHR20004（江苏恆瑞医药有限公司）
• AMG-133（安进）
• 1875 年（诺和诺德公司）
• 卡格列□（Novo Nordisk A/S）
• EMP-16-02（Empros 製药公司）

第I阶段

• EMP-16-02（Empros Pharma）
• AMG-786（Amgen）
• BMS-963272（Bristol-Myers Squibb）
• DD01（D&D Pharmatech）
• ERX1000（ERX Pharmaceuticals）
• GMA106（Gmax Biopharm）
• LY3457263（Eli Lilly and Company）
• NNC0247-0829（Novo Nordisk）
• 阿米克汀（Novo Nordisk）
• NO-13065（Otsuka Pharmaceutical Factory, Inc）
• S-309309（Shionogi）
• HM15136（Hanmi Pharmaceutical Company Limited）
• DR10624（Zhejiang Doer Biologics）
• LY3841136（Eli Lilly and Company）
• DACRA QW II（Eli Lilly and Company）
• AZD6234（AstraZeneca）
• CT-388（Carmot Therapeutics, Inc）
• INV-202（Inversago Pharma Inc.）
• BI 1820237（Boehringer Ingelheim）
• ZP 8396（Zealand Pharma）
• MVD1（Eolo pharma）
• VK2735（Viking Therapeutics）
• GSBR-1290（Structure Therapeutics）
• XW014（Sciwind Biosciences）
• CIN-109（CinFina Pharma）
• CB4211（CohBar）
• DWP306001（Daewoong Pharmaceutical）
• LR19021（LG Life Sciences）
• ECC5004（Eccogene）
• SCO267（SCOHIA PHARMA, Inc）
• SCO094（SCOHIA PHARMA, Inc./Huadong Medicine）
• BC LisPram（Adocia）
• GUB002496（Gubra Therapeutics/Boehringer Ingelheim）
• MT961（Medytox）

肥胖临床前管线景观

肥胖的SWOT分析

附录

Obesity report provides a comprehensive analysis of the obesity market, with an in-depth analysis of key pipeline products, licensing, acquisition, and collaboration deals. The report covers around 120+ products with 50 companies and their 65 products is clinical stages, providing valuable insights to companies seeking to expand their research in this therapy area. In addition, our report provides in-depth profiles of obesity candidates, including preclinical and clinical studies, details of partnerships and business deal values, targeted technologies, investments, and acquisition trends. We also provide licensing opportunities, acquisition trends, and product analysis by phases, company & MOA. Furthermore, the report covers descriptive information on the competitive pipeline landscape.

Obesity is a growing public health concern, with increasing prevalence worldwide. It has become so prevalent that it is now classified by the American Medical Association (2013) and the European Commission (2021) as a chronic disease. Obesity has a significant impact on quality of life and results in increased healthcare costs, with individuals with obesity at increased risk of developing numerous health risks, including cardiovascular disease, type 2 diabetes, certain cancers, and musculoskeletal disorders.

In this report, Mellalta Meets provides an in-depth analysis of Obesity pipeline covering Phase III & Phase II Pipeline Analysis Overview, Pipeline Products by Stage of Development, Obesity Competitive Landscape Distinguished by Phase & Route, Clinical Pipeline Products by Company, Obesity Monotherapy & Combinations Clinical Trials, Pipeline Products by MOA, Novel Mechanisms in Early and Clinical Stages , Obesity Clinical & Regulatory Timelines, Late-Stage Profiles Comparisons At-a-glance, details of partnerships and business deal values and investments. Currently, there are more than 65 candidates under evaluation in clinical and preclinical studies. The major key players operating in the market are Novo Nordisk, Merck & Co, Eli Lilly and Company, and Innovent Biologics (Suzhou) Co. Ltd and many more which have robust clinical pipelines of OBESITY inhibitor candidates. As per analysis, despite the challenges in the pipeline development of obesity, the obesity market looks set to become the next blockbuster pharma category.

Key Highlights of Obesity Report:

• The Obesity segment is dominated by the pre-clinical assets (XX) which represent XX% of the total development followed by Phase 1 assets (XX) representing XX%, Phase 2 assets (XX) with XX%, discovery (XX) with 13% and Phase 3 (4) representing 3% of the pipeline development in Obesity.

• The obesity treatment pipeline is marked by a strong presence of US-based biotech companies, accounting for an impressive XX% of all clinical-stage obesity therapies, followed by China and Denmark with XX%. With Eli Lilly leading the pack in product development, closely trailed by Novo Nordisk and Zealand Pharma, the obesity pipeline showcases a robust and diverse range of innovative solutions to address the global obesity epidemic. These industry giants are set to transform the landscape with ground-breaking treatments, tapping into new mechanisms of action and combination therapies for enhanced efficacy and improved patient adherence.

• Obesity pipeline landscape includes 85% of Monotherapy trials, 3% combination therapy and 12% of Combination/monotherapy trials.

• The Obesity segment is dominated by the pre-clinical assets (46), phase 1 assets (37), phase 2 assets (24) and phase 3 (4).

Report Coverage:

• Indication Prioritisation: Obesity market potential based on Indications.

• Business Transactions & Strategies: Key collaborations and deal values

• Obesity Pipeline Development: Product Profiles, Clinical Trials & Results

• Obesity Acquisition Targets

• Obesity Competitive Intelligence

• Recent & Upcoming events

TABLE OF CONTENTS

OVERVIEW

The Obesity Target BACKGROUND

• Introduction
• Epidemiology & Causes
• Pathophysiology of Obesity
• Obesity pathomechanisms
• Role of Glucagon-like peptide-1 (GLP-1) in obesity
• 2022 Obesity Treatment Guidelines
• Evidence-based recommendations for selecting the most appropriate weight loss medications for their patients
• Marketed Drugs in T2D (Type 2 diabetes) with potential outcomes in Obesity

Obesity PIPELINE ANALYSIS by Phases

• Obesity - Phase III & Phase II Pipeline Analysis Overview
• Pipeline Products by Stage of Development
• Obesity Competitive Landscape Distinguished by Phase & Route
• Clinical Pipeline (Phase 3 - Phase 1) Products by Company
• Obesity Monotherapy & Combinations Clinical Trials
• Pipeline Products by MOA
• Novel Mechanisms in Early and Clinical Stages
• Obesity Clinical & Regulatory Timelines
• Late-Stage Profiles Comparisons At-a-glance

Obesity Licensing, Acquisition And Collaboration

• Obesity Licensing, Acquisition, and Deal values
• Obesity Licensing by Transaction type and total amount size by Phases

Obesity Pipeline Landscape

• Obesity Clinical Pipeline Landscape

Phase III

• CagriSema (Novo Nordisk A/S)
  • Product Profile
  • Clinical Trials
  • Collaborations
  • Other Developments
• DOR/3TC/TDF (Merck & Co)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Tirzepatide (Eli Lilly and Company)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• IBI362 (Innovent Biologics (Suzhou) Co. Ltd.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Obesity Pipeline Landscape

Phase II

• DCCR (Soleno Therapeutics, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• MBL949 (Novartis)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• BI 456906 (Zealand Pharma/Boehringer Ingelheim)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• LY3502970 (Eli Lilly and Company)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• XW-003 (Sciwind Biosciences)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• ARD-101 (Aardvark Therapeutics)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Danuglipron (Pfizer)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• PF-07081532 (Sosei Heptares)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Pemvidutide (Altimmune, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Retatrutide (Eli Lilly and Company)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• TG103 (Genexine/I-Mab Biopharma/CSPC Pharmaceutical)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• APHD-012 (Aphaia Pharma)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Bimagrumab (Versanis Bio, Inc./ Novartis)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• HSG4112 (Glaceum)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• SHR20004 (Jiangsu HengRui Medicine Co.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• AMG-133 (Amgen)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• PYY 1875 (Novo Nordisk A/S)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Cagrilintide (Novo Nordisk A/S)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• EMP-16-02 (Empros Pharma)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments

Phase I

• EMP-16-02 (Empros Pharma)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• AMG-786 (Amgen)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• BMS-963272 (Bristol-Myers Squibb)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• DD01 (D&D Pharmatech)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• ERX1000 (ERX Pharmaceuticals)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• GMA106 (Gmax Biopharm)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• LY3457263 (Eli Lilly and Company)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• NNC0247-0829 (Novo Nordisk)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• Amycretin (Novo Nordisk)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• NO-13065 (Otsuka Pharmaceutical Factory, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• S-309309 (Shionogi)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• HM15136 (Hanmi Pharmaceutical Company Limited)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• DR10624 (Zhejiang Doer Biologics)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• LY3841136 (Eli Lilly and Company)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• DACRA QW II (Eli Lilly and Company)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• AZD6234 (AstraZeneca)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• CT-388 (Carmot Therapeutics, Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• INV-202 (Inversago Pharma Inc.)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• BI 1820237 (Boehringer Ingelheim)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• ZP 8396 (Zealand Pharma)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• MVD1 (Eolo pharma)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• VK2735 (Viking Therapeutics)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• GSBR-1290 (Structure Therapeutics)
  • Product Profile & Description
  • Clinical Trials
  • Collaborations
  • Other Developments
• XW014 (Sciwind Biosciences)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• CIN-109 (CinFina Pharma)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• CB4211 (CohBar)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• DWP306001 (Daewoong Pharmaceutical)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• LR19021 (LG Life Sciences)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• ECC5004 (Eccogene)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• SCO267 (SCOHIA PHARMA, Inc.)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• SCO094 (SCOHIA PHARMA, Inc./Huadong Medicine)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• BC LisPram (Adocia)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• GUB002496 (Gubra Therapeutics/Boehringer Ingelheim)
  • Product Profile & Description
  • Collaborations
  • Other Developments
• MT961 (Medytox)
  • Product Profile & Description
  • Collaborations
  • Other Developments

Obesity Pre-clinical Pipeline Landscape

Obesity SWOT Analysis

Appendix

• About us